Guerir Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 27-06-2024
- Paid Up Capital ₹ 0.10 M
as on 27-06-2024
- Company Age 8 Year, 22 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 M
as on 27-06-2024
- Satisfied Charges ₹ 1.50 M
as on 27-06-2024
- Revenue 4.26%
(FY 2020)
- Profit 3.45%
(FY 2020)
- Ebitda 3.76%
(FY 2020)
- Net Worth 95.60%
(FY 2020)
- Total Assets 10.58%
(FY 2020)
About Guerir Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.00 M. The company has closed loans amounting to ₹1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Amit Singh and Avinash Singh serve as directors at the Company.
- CIN/LLPIN
U52399DL2016PTC308768
- Company No.
308768
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Dec 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
West Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Guerir Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Avinash Singh  | Director | 01-Dec-2016 | Current |
| Amit Singh | Director | 29-Sep-2018 | Current |
Financial Performance of Guerir Pharmaceuticals.
Guerir Pharmaceuticals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 4.26% increase. The company also saw a slight improvement in profitability, with a 3.45% increase in profit. The company's net worth Soared by an impressive increase of 95.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Guerir Pharmaceuticals?
In 2020, Guerir Pharmaceuticals had a promoter holding of 70.00% and a public holding of 30.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Rama Multi Speciality Hospital & Trauma Centre Private LimitedInactive For E-Filing 8 months 22 days
Amit Singh is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 12 Sep 2017 | ₹3.00 M | Open |
Indian Overseas Bank Creation Date: 07 Feb 2017 | ₹1.50 M | Satisfied |
How Many Employees Work at Guerir Pharmaceuticals?
Guerir Pharmaceuticals has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Guerir Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Guerir Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
